Hexavalent DTaP-IPV-HB-Hib Vaccine Shows Immunogenicity in Preterm Infants
A phase IV trial in Spain found that a 2 + 1 schedule of the hexavalent DTaP-IPV-HB-Hib vaccine is immunogenic and well tolerated in preterm infants.
Asset / Drug
Drug and asset intelligence for Hexavalent with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
Vaccines
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.